These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16877657)

  • 1. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
    Hunter AM; Leuchter AF; Morgan ML; Cook IA
    Am J Psychiatry; 2006 Aug; 163(8):1426-32. PubMed ID: 16877657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder.
    Bares M; Brunovsky M; Kopecek M; Novak T; Stopkova P; Kozeny J; Sos P; Krajca V; Höschl C
    Eur Psychiatry; 2008 Aug; 23(5):350-5. PubMed ID: 18450430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early changes in prefrontal activity characterize clinical responders to antidepressants.
    Cook IA; Leuchter AF; Morgan M; Witte E; Stubbeman WF; Abrams M; Rosenberg S; Uijtdehaage SH
    Neuropsychopharmacology; 2002 Jul; 27(1):120-31. PubMed ID: 12062912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does prior antidepressant treatment of major depression impact brain function during current treatment?
    Hunter AM; Cook IA; Leuchter AF
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):711-20. PubMed ID: 22445212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QEEG Theta Cordance in the Prediction of Treatment Outcome to Prefrontal Repetitive Transcranial Magnetic Stimulation or Venlafaxine ER in Patients With Major Depressive Disorder.
    Bares M; Brunovsky M; Novak T; Kopecek M; Stopkova P; Sos P; Höschl C
    Clin EEG Neurosci; 2015 Apr; 46(2):73-80. PubMed ID: 24711613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.
    Hunter AM; Ravikumar S; Cook IA; Leuchter AF
    Acta Psychiatr Scand; 2009 Apr; 119(4):266-73. PubMed ID: 19077131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of improved mood over time in clinical trials for major depression.
    Marie-Mitchell A; Leuchter AF; Chou CP; James Gauderman W; Azen SP
    Psychiatry Res; 2004 Jun; 127(1-2):73-84. PubMed ID: 15261707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.
    Korb AS; Hunter AM; Cook IA; Leuchter AF
    Psychiatry Res; 2011 Jun; 192(3):188-94. PubMed ID: 21546222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in brain function of depressed subjects during treatment with placebo.
    Leuchter AF; Cook IA; Witte EA; Morgan M; Abrams M
    Am J Psychiatry; 2002 Jan; 159(1):122-9. PubMed ID: 11772700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo.
    Hunter AM; Leuchter AF; Morgan ML; Cook IA; Abrams M; Siegman B; DeBrota DJ; Potter WZ
    Neuropsychopharmacology; 2005 Apr; 30(4):792-9. PubMed ID: 15637637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
    Hunter AM; Muthén BO; Cook IA; Leuchter AF
    J Psychiatr Res; 2010 Jan; 44(2):90-8. PubMed ID: 19631948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The brain tells: early signs of depression recovery.
    Harv Ment Health Lett; 2002 Nov; 19(5):6. PubMed ID: 12453746
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression.
    Leuchter AF; Morgan M; Cook IA; Dunkin J; Abrams M; Witte E
    Psychopharmacology (Berl); 2004 Dec; 177(1-2):15-22. PubMed ID: 15252704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using prefrontal and midline right frontal EEG-derived theta cordance and depressive symptoms to predict the differential response or remission to antidepressant treatment in major depressive disorder.
    de la Salle S; Jaworska N; Blier P; Smith D; Knott V
    Psychiatry Res Neuroimaging; 2020 Aug; 302():111109. PubMed ID: 32480044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midline and right frontal brain function as a physiologic biomarker of remission in major depression.
    Cook IA; Hunter AM; Abrams M; Siegman B; Leuchter AF
    Psychiatry Res; 2009 Nov; 174(2):152-7. PubMed ID: 19853417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
    Sheehan DV; Nemeroff CB; Thase ME; Entsuah R;
    Int Clin Psychopharmacol; 2009 Mar; 24(2):61-86. PubMed ID: 19238088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A; Roose S
    Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R; Chen J; Entsuah AR; Schatzberg AF
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.